Videos

Peter Grivas, MD, PhD, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.

<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic&nbsp; or recurrent cervical cancer.</p>

Asymptomatic Relapsed Multiple Myeloma

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.

Kevin Staveley-O&rsquo;Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.

Ali McBride, PharmD, MS, BCOP, discusses the theme for his presidency: Collaborate. Educate. Compensate: A Prescription for Sustainable Cancer Care Delivery.<br /> &nbsp;

Relapsed/Refractory Multiple Myeloma

Pashtoon M. Kasi, MD, MBBS, MS, discusses the patient populations with colorectal cancer that are likely to benefit from immunotherapy treatment.

Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non&ndash;small cell lung cancer.

Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.

Kathleen G. Essel, MD, discusses the role of quantitative imaging feature analysis in gynecologic cancers.

Mark D. Pegram, MD, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.

Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.

Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br /> &nbsp;

Ursula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.